Indian Journal of Pharmacology Home 

CLINICAL RESEARCH ARTICLES
[View FULLTEXT] [Download PDF]
Year : 2020  |  Volume : 52  |  Issue : 5  |  Page : 372--377

Outcome of hepatitis C patients in a community with predominant genotype 3 with standard-of-care treatment before and after advent of direct-acting antivirals: A retrospective-cum-prospective study

Showkat Ahmad Kadla1, Mohamad Amin Dar2, Nisar Ahmad Shah1, Bilal Ahmad Khan1, Asif Iqbal Shah3, Rupakshi Pathania2, Shagufta Parveen4 
1 Professor, Department of Gastroenterology, Govt. Medical College, Srinagar, India
2 Post Graduate Scholar, Department of Medicine, Govt. Medical College, Srinagar, India
3 Registrar, Department of Gastroenterology, Govt. Medical College, Srinagar, India
4 Associate Professor, Deparment of Pharmacology, Govt. Medical College, Srinagar, India

Correspondence Address:
Dr. Nisar Ahmad Shah
Professor, Department of Gastroenterology, Govt. Medical College, Srinagar, Jammu and Kashmir
India

BACKGROUND AND OBJECTIVE: Chronic hepatitis, cirrhosis, and hepatocellular carcinoma are mainly caused by hepatitis C infection. It is a worldwide predominant pathogen and is one of the main causes of healthcare problem in Asia. In the last few decades, there has been a considerable change in the treatment regimen for hepatitis C virus. The objective of this research was to relate the treatment response with sustained viral response in various therapies which have been the standard of care from time to time. MATERIALS AND METHODS: This hospital-based, retrospective-cum-prospective research span over a period of 2 years; we enrolled hepatitis C patients who attended the Department of Gastroenterology and Hepatology, Government Medical College, Srinagar, since June 2015 till May 2017. Subsequently, the database was prepared, containing all the relevant information about these patients. RESULTS: [INLINE:1] CONCLUSIONS: (i) In retrospective group: The overall efficacy (sustained viral response at 24 weeks [SVR-24]) of pegylated interferon a2a and ribavirin regimen was 90.96%. (ii) In prospective group: The efficacy (SVR) of different regimens was found to be as: sofosbuvir + ribavirin + daclatasvir (SVR-24, 83.33%); sofosbuvir + ribavirin (SVR-12, 94.57%); and sofosbuvir + daclatasvir (SVR-12, 98.00%).


How to cite this article:
Kadla SA, Dar MA, Shah NA, Khan BA, Shah AI, Pathania R, Parveen S. Outcome of hepatitis C patients in a community with predominant genotype 3 with standard-of-care treatment before and after advent of direct-acting antivirals: A retrospective-cum-prospective study.Indian J Pharmacol 2020;52:372-377


How to cite this URL:
Kadla SA, Dar MA, Shah NA, Khan BA, Shah AI, Pathania R, Parveen S. Outcome of hepatitis C patients in a community with predominant genotype 3 with standard-of-care treatment before and after advent of direct-acting antivirals: A retrospective-cum-prospective study. Indian J Pharmacol [serial online] 2020 [cited 2021 Dec 3 ];52:372-377
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2020;volume=52;issue=5;spage=372;epage=377;aulast=Kadla;type=0